Oragenics and BRAINBox Partner to Advance Concussion Diagnosis and Treatment
Oragenics teams up with BRAINBox to develop a first-of-its-kind intranasal therapy for concussions.
Oragenics, Inc. has announced a strategic partnership with BRAINBox Solutions to develop an innovative "trigger-to-treat" platform for mild traumatic brain injuries (mTBI), commonly known as concussions. This collaboration integrates BRAINBox’s AI-driven diagnostic technology with Oragenics’ ONP-002, a novel intranasal therapeutic designed to reduce brain injury effects and promote recovery. Together, they aim to transform TBI care by enabling early detection, predictive prognosis, and targeted treatment.
“This partnership is a major step forward in concussion management,” said Janet Huffman, Interim CEO of Oragenics. “By combining BRAINBox’s diagnostic platform with our therapeutic candidate, we can improve patient outcomes and enhance clinical trial precision.” With over 5 million concussions occurring annually in the U.S., this collaboration could redefine concussion treatment, setting new standards for rapid intervention and personalized care.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Medicus Pharma reicht Phase‑2b/3‑Protokoll für Teverelix bei der FDA ein
Fresenius Kabi erhält FDA-Warnschreiben nach Fehlern bei der Untersuchung aseptischer Verarbeitung in der Anlage Melrose Park
Discussion